Table 2. Risk groups for localised prostate cancer.
Parameter | Low risk | Intermediate risk | High risk |
Tumour stage | T1–T2a and | T2b–T2c or | T3a or |
Gleason score | 2–6 and | 7 or | 8–10 or |
Pre-treatment PSA | ≤10 ng ml–1 | 10–20 ng ml–1 | >20 ng ml–1 |
PSA, prostate-specific antigen.